Decentralized clinical trials for medications to reduce the risk of dementia: consensus report and guidance

INTRODUCTION: Recent growth in the functionality and use of technology has prompted an increased interest in the potential for remote or decentralized clinical trials in dementia. There are many potential benefits associated with decentralized medication trials, but we currently lack specific recomm...

Full description

Autores:
Howard, Leanne
Abdelnour, Carla
Abner, Erin L.
Allegri, Ricardo F.
Dodge, Hiroko H.
Gauthier, Serge
Hoyos, Camilla M.
Jicha, Gregory A.
Kehoe, Patrick G.
Mummery, Catherine J.
Ogunniyi, Adesola
Scarmeas, Nikolaos
Tipo de recurso:
Article of investigation
Fecha de publicación:
2024
Institución:
Corporación Universidad de la Costa
Repositorio:
REDICUC - Repositorio CUC
Idioma:
eng
OAI Identifier:
oai:repositorio.cuc.edu.co:11323/13666
Acceso en línea:
https://hdl.handle.net/11323/13666
https://repositorio.cuc.edu.co/
Palabra clave:
Decentralized clinical trials
Delphi process
Dementia prevention
Recommendations
Remote clinical trials
Rights
openAccess
License
Atribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)
Description
Summary:INTRODUCTION: Recent growth in the functionality and use of technology has prompted an increased interest in the potential for remote or decentralized clinical trials in dementia. There are many potential benefits associated with decentralized medication trials, but we currently lack specific recommendations for their delivery in the dementia field. METHODS: A modified Delphi method engaged an expert panel to develop recommendations for the conduct of decentralized medication trials in dementia prevention. A working group of researchers and clinicians with expertise in dementia trials further refined the recommendations. RESULTS: Overall, the recommendations support the delivery of decentralized trials in dementia prevention provided adequate safety checks and balances are included. A total of 40 recommendations are presented, spanning aspects of decentralized clinical trials, including safety, dispensing, outcome assessment, and data collection. DISCUSSION: These recommendations provide an accessible, pragmatic guide for the design and conduct of remote medication trials for dementia prevention. Highlights: Clinical trials of medication have begun adopting decentralized approaches. Researchers in the field lack guidance on what would be appropriate circumstances and frameworks for what would be appropriate circumstances and frameworks for the use of decentralized trial methods in dementia prevention. The present report provides consensus-based expert recommendations for decentralized clinical trials for dementia prevention.